title: [Juvenile idiopathic arthritis. II. Treatment and prognosis].
abstract: Immunosuppressants, including methotrexate and more recently anti-TNFalpha, have modified the prognosis of the most severe forms juvenile idiopathic arthritis. However, the therapeutic management is still challenging and adjuvant therapies, including physiotherapy, surgery, or even bisphosphonates and growth hormone, are still widely used to limit the negative impact of an extended general corticotherapy.
authors: Unit d'immunologie-hématologie et rhumatologie pédiatriques, Centre de référence national labellisé Arthrites juvéniles, hôpital Necker-Enfants malades, 75743 Paris. quartier@necker.fr
authors: Pierre
authors: P
authors: Quartier
authors: Anne-Marie
authors: AM
authors: Prieur
mesh_terms: D000293:Adolescent; D001171:Arthritis, Juvenile / Q000150:complications / Q000628:therapy*; D002648:Child; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D026741:Physical Therapy Modalities; D011379:Prognosis; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha